Press Release

Cleanascite™ Cited in Study of Adipocyte Lipids in the Tumor Microenvironment

MONMOUTH JUNCTION, NJ, November 18, 2025 — Biotech Support Group (BSG) reports on its proprietary lipid removal reagent, Cleanascite™, in a cell response study of CD8 + T cells in the tumor microenvironment.

Researchers from Shanghai Jiao Tong University School of Medicine, published an article entitled “Cancer-associated adipocytes mediate CD8 + T cell dysfunction via FGF21-driven lipolysis”, investigating whether fatty acids released by cancer-associated adipocytes (CAAs) are critical for CD8 + T cell exhaustion in the tumor microenvironment.

The article states “To determine whether fatty acids released by CAAs are critical for CD8 + T cell exhaustion, we depleted fatty acids from CAA conditioned medium with Cleanascite prior to incubation with CD8 + T cells. Strikingly, fatty acid depletion in CAA-conditioned medium resulted in decreased fatty acid uptake and lipid peroxidation in CD8 + T cells (Figure 2G). Accordingly, CAA-induced CD8 + T cell exhaustion was significantly attenuated (Figures 2H and S2G),

whereas the cytotoxic function of CD8 + T cells was notably recovered after fatty acid depletion (Figures 2I and S2H). These data suggest that fatty acids from CAAs are responsible for CD8 + T cell dysfunction.”

“Here is another excellent example of how Cleanascite™ can be used to clear lipids from conditioned media. Most importantly, this resulted in the identification of fatty acids as the determining driver for T cell exhaustion. As a solid-phase suspension, Cleanascite™ is perfectly suited to investigate lipid influences on cell response assays such as this.” stated Dr. Swapan Roy, President and Founder of Biotech Support Group.

For additional product details, visit:
Cleanascite™ Lipid Removal Reagent

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: [email protected]

Keywords: Cleanascite™, lipid depletion, fatty acids, cancer-associated adipocytes, tumor microenvironment, CD8 + T cell exhaustion